atrial fibrillation

1. Oxypeucedanin ((+-)-Oxypeucedanin) has novel anticancer effect, mediated via induction of G2-M cell cycle arrest and apoptosis in human prostate carcinoma DU145 cells. 2. Oxypeucedanin is a kind of open-channel blocker of the hKv1.5 channel and it prolongs the APD; therefore, it is an excellent candidate as an antiarrhythmic drug for atrial fibrillation.

2-Hydroxybenzylamine, a potent small molecule scavenger of IsoLGs, sequesters the reactive species as inert adducts. 2-Hydroxybenzylamine may be used to decrease early recurrence of atrial fibrillation and other atrial arrhythmias following atrial fibrillation ablation by decreasing IsoLG adducts with native biomolecules.

Sulamserod (RS 100302) is a potent 5-HT4 receptor antagonist with antiarrhythmic activity for the study of atrial fibrillation and cardiovascular related diseases.

AVE-0118 is a potassium channel blocker and suppresses persistent atrial fibrillation.

Selodenoson (RG-14202) is a selective adenosine A1 receptor agonist used to slow the heart rate in patients with atrial fibrillation and to treat arrhythmias.

BMS-394136 (BMS 394136) is a KV1.5 antagonist for the treatment of cardiovascular diseases such as arrhythmias and atrial fibrillation.

BMS-919373 is a potassium channel Kv1.5 (KCNA5) inhibitor for atrial fibrillation and acute coronary syndrome.

Cavutilide has antiarrhythmic activity, inhibits hERG K(+) channels, and can be used to study heart failure and persistent atrial fibrillation.

Celivarone is a potassium channel blocker used in the study of arrhythmias, atrial flutter and atrial fibrillation.

Sulcardine 2HCl is a multi-ion channel blocker with antiarrhythmic effects that blocks the properties of hERG and hNav1.5 channels and can be used to study atrial fibrillation and ventricular arrhythmias.

Dabigatran etexilate (BIBR 1048) is a thrombin inhibitor that binds to thrombin, blocking its thrombogenic activity and preventing thrombus formation.

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Dronedarone hydrochloride (SR33589) is an amiodarone analog which has an effective and promising treatment for Atrial fibrillation.

Dabigatran Etexilate Mesylate (BIBR 1048MS) is the orally active prodrug of dabigatran. Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI, Ki: 4.5 nM).

Dofetilide (UK 68789) is a sulfonamide class III antiarrhythmic agent and potassium channel blocker. Dofetilide selectively blocks cardiac ion channels of the rapid component of the delayed rectifier potassium current Ikr. This antiarrhythmic agent prolongs cardiac action potential duration and effective refractory period due to delayed repolarization without affecting conduction velocity. This results in a normal sinus rhythm. Dofetilide is used in the treatment of atrial fibrillation and flutter.

AVE1231 is a TASK-1 channel blocker that inhibits TASK-1 and can be used in the study of atrial fibrillation.

Euphornin is a diterpene natural product isolated from Euphorbia dulcis that inhibits G protein-activated inwardly rectifying potassium channels GIRK1/4 (Kir3.1/3.4) with an IC50 of 2.63 µM, making it useful for studying atrial fibrillation.

Aprindine HCl is a Class 1b antiarrhythmic agent used to manage ventricular and supraventricular arrhythmias. In one study, it delayed atrial fibrillation more than digoxin did. It has shown effectiveness when given orally.

Flecainide is an orally administered antiarrhythmic agent acting as a sodium channel blocker and IKr inhibitor, indicated for the treatment of paroxysmal supraventricular tachycardia (PSVT).

Atecegatran Metoxil (Atecegatran Fexenetil ,AZD0837) is an oral direct thrombin inhibitor,which currently in clinical development for the prevention of stroke and systemic embolic events in patients with atrial fibrillation. AZD0837 is a selective and re

Budiodarone(ATI-2042)is a chemical analog of an antiarrhythmic drug and amiodarone. Budedalone is promising as an antiarrhythmic agent for the prevention of atrial fibrillation.

C1 resveratrol is a novel multifunctional derivative of resveratrol, which is used to treat atrial fibrillation.

KCa2 (small conductance Ca2+-activated potassium) channel negative allosteric modulator (IC50 = 1.1 μM). Increases the EC50 of Ca2+ on KCa2.3 channels by ~3-fold. Prolongs atrial effective refractory period (AERP) in rats. Reduces atrial fibrillation (AF) duration and prolongs atrial refractoriness without affecting ventricular refractory period in an animal AF model. Diness et al (2017) Termination of vernakalant-resistant atrial fibrillation by inhibition of small-conductance Ca2+-activated K+ channels in pigs. Circ.Arrhythm.Electrophysiol. 10 e005125 PMID:29018164 |Simó-Vicens et al (2017) A new negative allosteric modulator, AP14145, for the study of small conductance calcium-activated potassium (KCa2) channels. Br.J.Pharmacol. 174 4396 PMID:28925012

AP14145 hydrochloride is a potent negative allosteric modulator of K Ca 2 (SK) channels, specifically targeting K Ca 2.2 (SK2) and K Ca 2.3 (SK3) channels with an IC 50 of 1.1 μM. Inhibition of AP14145 hydrochloride is highly influenced by S508 and A533 amino acids present in the channel. This compound effectively extends the atrial effective refractory period (AERP) in rats and exhibits antiarrhythmic properties in a Vernakalant-resistant porcine model of atrial fibrillation (AF).